igan clinical trial

Back to Top

Clinical Trial: ARTEMIS-IGAN

Omeros Corporation is sponsoring the ARTEMIS-IGAN clinical trial, a randomized, double-blind, placebo-controlled, Phase 3 study of the safety and efficacy of narsoplimab in patients with immunoglobulin A (IgA) nephropathy.

The purpose of this clinical trial is to see if the investigational drug narsoplimab is safe in people with IgA nephropathy and can help to treat IgA nephropathy.

  • The primary outcome measure is the change in urine protein excretion at 36 weeks.
  • This clinical trial is being conducted in patients aged 18 years and older who have a diagnosis of IgA nephropathy and meet other eligibility criteria.
  • After screening and evaluation, those taking part will receive either narsoplimab or placebo for 12 weeks.
  • Those who do not respond will be considered for an additional six weeks of treatment.
Back to Top

What is IgA Nephropathy?

IgA Nephropathy
IgA Nephropathy (also known as Berger's disease) is a progressive autoimmune disease that results in chronic inflammation of the kidneys and leads to reduced kidney function over time. The kidneys’ primary function is to filter the blood to remove waste and excess fluid. IgA nephropathy damages the kidneys’ ability to function properly. Show more
IgA Nephropathy - A high unmet medical need
There is no cure for IgA nephropathy and there are currently no approved medications for specifically treating the disease. Show more
Role of Complement in IgA Nephropathy
The complement system is part of the immune system, which helps the body defend against tissue damage and infections. Show more
Narsoplimab for the Treatment of IgA Nephropathy
Narsoplimab (also known as OMS721) is Omeros Corporation’s investigational drug that targets the complement system’s lectin pathway. Show more
Back to Top

Role of Complement in IgA Nephropathy

About Clinical Research

About Omeros

Omeros Corporation is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancer.

Narsoplimab, a MASP-2 complement inhibitor, is an investigational drug and is not yet approved by the FDA or any other regulatory agency as a treatment for any indication.